Durham, NC, United States · North America
OncologyRare diseaseCell & gene therapyVaccines
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare diseaseVaccines
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare disease
NMPAFDA
SCALE 190 studies
Open to sponsorsSterile / advanced-therapy specialistView Durham, NC, United States · United States
Rare diseaseOncologyCell & gene therapy
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyVaccinesRare disease
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView Oncology
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView E
Guildford, United Kingdom · Europe
OncologyRare disease
FDAEMAMHRA
SCALE 260 studies
Open to sponsorsAdvanced-therapy activeView M
Cincinnati, OH, United States · United States
OncologyRare disease
FDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyCell & gene therapy
NMPAFDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView Morrisville, NC, United States · United States
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyRare disease
PMDAFDAEMANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView PC
Zug, Switzerland · Europe
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView London, United Kingdom · Europe
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 230 studies
Open to sponsorsSelectiveView Not stated as a therapeutic-area list. The company names immuno-oncology and T-cell biology as biologics/discovery focus areas; its offering is otherwise described by modality (small moleculespeptidesoligonucleotidesmAbs
FDA
SCALE 00 studies
Open to sponsorsSelectiveView